A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.

Isao KawaguchiKazuaki ChayamaYuri Sanchez GonzalezSuchin VirabhakDominic MitchellCammy YuenHiromitsu Kumada

Published in: Advances in therapy (2019)

In GT1 treatment-naïve non-cirrhotic patients GLE/PIB was a cost-effective strategy compared to other DAAs. When a pan-genotypic framework was used, the GLE/PIB portfolio dominated the SOF-based portfolio.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
pet imaging
prognostic factors
combination therapy
positron emission tomography